Free Trial

Doximity (DOCS) Stock Forecast & Price Target

Doximity logo
$57.83 +2.65 (+4.80%)
(As of 12/20/2024 05:51 PM ET)

Doximity - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
13
Buy
7

Based on 20 Wall Street analysts who have issued ratings for Doximity in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 13 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for DOCS.

Consensus Price Target

$52.59
-9.06% Downside
According to the 20 analysts' twelve-month price targets for Doximity, the average price target is $52.59. The highest price target for DOCS is $75.00, while the lowest price target for DOCS is $32.00. The average price target represents a forecasted downside of -9.06% from the current price of $57.83.
Get the Latest News and Ratings for DOCS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Doximity and its competitors.

Sign Up

DOCS Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
13 Hold rating(s)
11 Hold rating(s)
8 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$52.59$52.27$32.42$28.40
Forecasted Upside-9.06% Downside8.43% Upside-21.89% Downside1.72% Upside
Consensus Rating
Hold
Hold
Hold
Hold

DOCS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DOCS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Doximity Stock vs. The Competition

TypeDoximityMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-9.06% Downside25,827.32% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent DOCS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/20/2024Stephens
4 of 5 stars
J. Garro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$55.00-0.33%
12/4/2024Mizuho
3 of 5 stars
S. Valiquette
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$55.00+1.48%
11/21/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$30.00 ➝ $48.00-4.15%
11/15/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$58.00+11.43%
11/14/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$35.00 ➝ $49.00-6.72%
11/14/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$33.00 ➝ $53.00+0.23%
11/13/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$40.00 ➝ $60.00+3.32%
11/11/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$52.00 ➝ $75.00+24.98%
11/8/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$37.00 ➝ $65.00+11.00%
11/8/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Schoenhaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSector Weight ➝ Overweight$70.00+61.22%
11/8/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Berenshteyn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$19.00 ➝ $41.00-5.57%
10/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line ➝ In-Line$34.00 ➝ $45.00+0.74%
10/7/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$32.00 ➝ $45.00+2.67%
9/17/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
V. Kesavabhotla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/17/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$41.00 ➝ $45.00+14.10%
8/9/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Berg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$38.00+48.03%
5/17/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$32.00+13.11%
11/10/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$21.00 ➝ $23.00-3.48%
8/9/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:46 AM ET.


DOCS Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Doximity is $52.59, with a high forecast of $75.00 and a low forecast of $32.00.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last year. There are currently 13 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares.

According to analysts, Doximity's stock has a predicted downside of -9.06% based on their 12-month stock forecasts.

Over the previous 90 days, Doximity's stock had 4 upgrades and 1 downgrade by analysts.

Analysts like Doximity less than other "medical" companies. The consensus rating for Doximity is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DOCS compares to other companies.


This page (NASDAQ:DOCS) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners